Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Phase I-II Study of Trastuzumab in Combination With RAD001 in Patients With HER-2 Overexpressing, PTEN-deficient Metastatic Breast Cancer Progressing on Trastuzumab-Based Therapy
Sponsor: M.D. Anderson Cancer Center
Listed as NCT00317720, this PHASE1/PHASE2 trial focuses on Breast Cancer and Neoplasm Metastasis and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 12 times since 2006, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2023 — Nov 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 7 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Nov 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .